Focal boost SBRT in men with intermediate- and high-risk PCa: 5-year results of the hypo-FLAME trial

被引：0
|
作者：
Draulans, Cedric [1 ]
Haustermans, Karin [1 ,2 ]
Pos, Floris J. [3 ]
van der Heide, Uulke A. [3 ]
De Cock, Lisa [1 ]
van Zyp, Jochem R. N. Van der Voort [4 ]
de Boer, Hans C. J. [4 ]
Smeenk, Robert Jan [5 ]
Kunze-Busch, Martina [5 ]
Monninkhof, Evelyn M. [6 ]
De Roover, Robin [2 ]
Isebaert, Sofie [2 ]
Kerkmeijer, Linda G. W. [4 ,5 ]
机构：
[1] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium
[2] Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium
[3] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands
[6] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
Prostate cancer; SBRT; Focal boost;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3396
引用
收藏
页码：S2647 / S2649
页数：4
相关论文
共 50 条
  • [11] Concomitant Hypofractionated IMRT Boost for High-Risk Prostate Cancer: 5 Year Results
    Cheung, P.
    Loblaw, D.
    Szumacher, E.
    Danjoux, C.
    Choo, R.
    Zhang, L.
    Mamedov, A.
    Deabreu, A.
    Morton, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S106 - S106
  • [12] High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort
    Marotte, Delphine
    Gal, Jocelyn
    Schiappa, Renaud
    Gautier, Mathieu
    Boulahssass, Rabia
    Chand-Fouche, Marie-Eve
    Hannoun-Levi, Jean-Michel
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 35 : 104 - 109
  • [13] A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer
    Oermann, Eric K.
    Slack, Rebecca S.
    Hanscom, Heather N.
    Lei, Sue
    Suy, Simeng
    Park, Hyeon U.
    Kim, Joy S.
    Sherer, Benjamin A.
    Collins, Brian T.
    Satinsky, Andrew N.
    Harter, K. William
    Batipps, Gerald P.
    Constantinople, Nicholas L.
    Dejter, Stephen W.
    Maxted, William C.
    Regan, James B.
    Pahira, John J.
    McGeagh, Kevin G.
    Jha, Reena C.
    Dawson, Nancy A.
    Dritschilo, Anatoly
    Lynch, John H.
    Collins, Sean P.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2010, 9 (05) : 453 - 462
  • [14] Long-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial
    Chatterjee, R.
    Chan, J.
    Mayles, H.
    Cicconi, S.
    Syndikus, I.
    CLINICAL ONCOLOGY, 2024, 36 (12) : e473 - e482
  • [15] LONG TERM RESULTS OF A PROSPECTIVE DOSE ESCALATION PHASE-II TRIAL: INTERSTITIAL PDR-BRACHYTHERAPY AS BOOST FOR INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Strnad, V.
    Lettmaier, S.
    Lotter, M.
    Kreppner, S.
    Strnad, A.
    Fietkau, R.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S87 - S87
  • [16] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials
    Roach, Mack, III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3816 - 3817
  • [17] Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients
    Agoston, Peter
    Major, Tibor
    Froehlich, Georgina
    Szabo, Zoltan
    Loevey, Jozsef
    Fodor, Janos
    Kasler, Miklos
    Polgar, Csaba
    BRACHYTHERAPY, 2011, 10 (05) : 376 - 384
  • [18] Quality of Life After IMRT or IMRT plus HDR Brachytherapy for Intermediate- or High-Risk Prostate Cancer: 8-Year Results of a Prospective Trial
    Guix, B.
    Lacorte, T.
    Bartrina, J.
    Tello, J.
    Guix, I.
    Galdon, G.
    Espino, M.
    Guix, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S386 - S386
  • [19] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials - In reply
    Nguyen, Paul L.
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3817 - 3818
  • [20] Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer
    Fecteau, Ryan E.
    Koontz, Bridget F.
    Hoffman, Karen E.
    Halabi, Susan
    Howard, Lauren E.
    Anand, Monika
    George, Daniel J.
    Zhang, Tian
    Berry, William R.
    Lee, W. Robert
    Harrison, Michael R.
    Corn, Paul G.
    Armstrong, Andrew J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
12345